Skip Navigation

This Article
Right arrow FREE Full Text (PDF) Freely available
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (25)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Hilkens, P. H. E.
Right arrow Articles by van den Bent, M. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Hilkens, P. H. E.
Right arrow Articles by van den Bent, M. J.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Annals of Oncology 8:187-190, 1997
© 1997 European Society for Medical Oncology

research-article

Clinical characteristics of severe peripheral neuropathy induced by docetaxel (Taxotere)

P. H. E. Hilkens1, J. Verweij2, Ch. J. Vecht1, G. Stoter2 and M. J. van den Bent1,

1Department of Neuro-Oncology Rotterdam, the Netherlands
2Department of Medical Oncology, Rotterdam Cancer Institute and University Hospital Rotterdam, the Netherlands

Correspondence to: M.J. van den Bent, MD, PhD Department of Neuro-Oneology Dr. Daniel den Hoed Cancer Center P.O. Box 5201 3008 A E Rotterdam The Netherlands

BACKGROUND:: Docetaxel, a semi-synthetic taxane may cause a usually mild sensory neuropathy. We describe the clinical characteristics of five patients who developed a more severe neuropathy following treatment with docetaxel.

PATIENTS AND METHODS:: All patients were treated in phase II studies with 100 mg/m2 docetaxel in three weekly cycles, without steroid administration.

RESULTS:: The clinical picture in these patients was dominated by a sensory neuropathy, but in one case severe weakess was present. Another patient developed Lhermitte's sign. Signs and symptoms are usually reversible after discontinuation of docetaxel administration, but in three patients symptoms worsened for some time after the end of treatment before improvement occurred.

CONCLUSION:: Severe docetaxel neuropathy may especially occur following treatment with cumulative dosage over 600 mg/m2; in patients treated with this dosage a moderate or severe neuropathy may not be rare.

docetaxel, Lhermitte's sign, neuropathy, taxotere


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Ann OncolHome page
O. Mir, J. Alexandre, A. Tran, J.-P. Durand, G. Pons, J.-M. Treluyer, and F. Goldwasser
Relationship between GSTP1 Ile105Val polymorphism and docetaxel-induced peripheral neuropathy: clinical evidence of a role of oxidative stress in taxane toxicity
Ann. Onc., April 1, 2009; 20(4): 736 - 740.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
J. M. Jurado, B. Pajares, D. Olmos, I. Sevilla, and E. Alba
'Out of blue' Lhermitte's sign: three cases due to low cumulative doses of oxaliplatin
Ann. Onc., December 1, 2008; 19(12): 2093 - 2094.
[Full Text] [PDF]

Home page
 Am J Health Syst PharmHome page
S. Y. Barbour
Caring for the treatment-experienced breast cancer patient: The pharmacist's role
Am. J. Health Syst. Pharm., May 15, 2008; 65(10_Supplement_3): S16 - S22.
[Abstract] [Full Text] [PDF]

Home page
 JDRHome page
R. Benoliel, J. Epstein, E. Eliav, R. Jurevic, and S. Elad
Orofacial Pain in Cancer: Part I--Mechanisms
Journal of Dental Research, June 1, 2007; 86(6): 491 - 505.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
R. Plummer, M. Ghielmini, P. Calvert, M. Voi, J. Renard, G. Gallant, E. Gupta, H. Calvert, and C. Sessa
Phase I and Pharmacokinetic Study of the New Taxane Analog BMS-184476 Given Weekly in Patients with Advanced Malignancies
Clin. Cancer Res., September 1, 2002; 8(9): 2788 - 2797.
[Abstract] [Full Text] [PDF]

Home page
 Hum Exp ToxicolHome page
S Teo, M Evans, J Ehrhart, M Brockman, D Allen, M Morgan, D Stirling, and S Thomas
Lack of peripheral neuropathy in Beagle dogs after 53 weeks oral administration of thalidomide capsules
Human and Experimental Toxicology, November 1, 2000; 19(11): 615 - 622.
[Abstract] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.